日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Leveraged Vaccination to Alleviate Original Antigenic Sin for Enhancing Broad-Neutralizing Antibody Response against SARS-CoV-2 Omicron Subvariants.

利用疫苗接种减轻原始抗原罪,以增强针对 SARS-CoV-2 Omicron 亚型的广谱中和抗体反应

Zhang Guangxu, Wang Qian, Ji Kai, Wang Yuanzhou, Xu Wei, Zhou Jie, Liu Zezhong, Xiu Ruixue, Xing Lixiao, Zhou Jianghao, Shi Yuren, Lu Xishan, Wang Xuanyi, Ying Bo, Lu Lu, Jiang Shibo

Predicted early fusion intermediates in the spike of ACE2-utilising bat coronavirus unveil broad-spectrum antiviral mechanisms

预测的蝙蝠冠状病毒刺突蛋白中早期融合中间体(利用ACE2)揭示了广谱抗病毒机制

Sun, Lujia; Liu, Zhimin; Xing, Lixiao; Liang, Xiaoxing; Lu, Lu; Jiang, Shibo; Sun, Lei; Wang, Xinling

Alpaca-derived nanobody targeting the hydrophobic pocket of the HIV-1 gp41 NHR broadly neutralizes HIV-1 by blocking six-helix bundle formation

源自羊驼的纳米抗体靶向HIV-1 gp41 NHR的疏水口袋,通过阻断六螺旋束的形成来广泛中和HIV-1。

Sun, Lujia; Chen, Bo; Liu, Xianbo; Zhu, Yun; Zhang, Guangxu; Liang, Xiaoxing; Xing, Lixiao; Xu, Wei; Jiang, Shibo; Wang, Xinling

Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor

格里菲辛及其二价进入抑制剂对甲型流感病毒和SARS-CoV-2感染或共同感染的抑制作用

Cao, Najing; Cai, Yanxing; Huang, Xin; Jiang, Hanxiao; Huang, Ziqi; Xing, Lixiao; Lu, Lu; Jiang, Shibo; Xu, Wei

Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines

开发可抵御变异株的严重急性呼吸综合征冠状病毒2、泛沙贝病毒和泛β冠状病毒疫苗

Zhou, Jie; Liu, Zezhong; Zhang, Guangxu; Xu, Wei; Xing, Lixiao; Lu, Lu; Wang, Qian; Jiang, Shibo

Molecular characterization of avian leukosis virus subgroup J in Chinese local chickens between 2013 and 2018

2013年至2018年中国地方鸡禽白血病病毒J亚群的分子特征

Ma, Meige; Yu, Mengmeng; Chang, Fangfang; Xing, Lixiao; Bao, Yuanling; Wang, Suyan; Farooque, Muhammad; Li, Xinyi; Liu, Peng; Chen, Yuntong; Qi, Xiaole; Pan, Qing; Gao, Li; Li, Kai; Liu, Changjun; Zhang, Yanping; Cui, Hongyu; Wang, Xiaomei; Sun, Yanming; Gao, Yulong